dc.contributor.author | Sedionoto, Blego | |
dc.date.accessioned | 2024-01-03T08:50:54Z | |
dc.date.available | 2024-01-03T08:50:54Z | |
dc.date.issued | 2023-08-19 | |
dc.identifier.citation | - | en_US |
dc.identifier.uri | https://www.journalajrrop.com | |
dc.identifier.uri | http://repository.unmul.ac.id/handle/123456789/55734 | |
dc.description | - | en_US |
dc.description.abstract | Aims: to report a case of retrobulbar optic neuritis (ON) associated with certolizumab.
Case report: A 22-year-old man presented with a 4 days history of decreased vision in the left eye accompanied by pain on extraocular movement. He had received an infusion of certolizumab for juvenile idiopathic arthritis 3 weeks before symtomatology. Ocular examination of the left eye revealed a left afferent pupillary defect. The best-corrected visual acuity was 1/10. Anterior segment and fundoscopy were normal. Visual evoked potentials a prolonged latency of the P100 in the left eye. Diagnosis of certolizumab-induced retrobulbar ON was made. Certolizumab was discontinued and the patient was treated with corticosteroids with good visual outcome.
Discussion: Occurrence of ON during treatment with anti-tumor necrosis factor α was reported in the literature, mainly with etanercept, then infliximab and adalimumab. There are few cases of ON associated with certolizumab.
Conclusion: This case illustrates the possibility of ON during treatment with certolizumab. Careful monitoring of patients receiving this therapy is necessary to identify ophthalmological or neurological side effects. | en_US |
dc.description.sponsorship | - | en_US |
dc.language.iso | en | en_US |
dc.publisher | Asian Journal of Research and Reports in Ophthalmology | en_US |
dc.relation.ispartofseries | -;- | |
dc.subject | biologic therapy, tumor necrosis factor-alpha, optic neuritis, adverse events | en_US |
dc.title | Peer Review manuscript Ms_AJRROP_107125: Retrobulbar optic neuritis associated with certolizumab | en_US |
dc.title.alternative | - | en_US |
dc.type | Other | en_US |